top
Please input keywords
Order
*Country
United States
China
France
Germany
Netherlands
United Kingdom
Japan
South Korea
Israel
Australia
Hong Kong, China
New Zealand
Russia
Singapore
Taiwan, China
India
Aland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua & Barbuda
Argentina
Armenia
Aruba
Ascension Island
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
British Indian Ocean Territory
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Canary Islands
Cape Verde
Caribbean Netherlands
Cayman Islands
Central African Republic
Ceuta & Melilla
Chad
Chile
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo - Brazzaville
Congo - Kinshasa
Cook Islands
Costa Rica
Côte d’Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czechia
Denmark
Diego Garcia
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
Indonesia
Iran
Iraq
Ireland
Isle of Man
Italy
Jamaica
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau, China
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar (Burma)
Namibia
Nauru
Nepal
New Caledonia
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territories
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Islands
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Rwanda
Samoa
San Marino
São Tomé & Príncipe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia & South Sandwich Islands
South Sudan
Spain
Sri Lanka
St. Barthélemy
St. Helena
St. Kitts & Nevis
St. Lucia
St. Martin
St. Pierre & Miquelon
St. Vincent & Grenadines
Sudan
Suriname
Svalbard & Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Tajikistan
Tanzania
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad & Tobago
Tristan da Cunha
Tunisia
Turkey
Turkmenistan
Turks & Caicos Islands
Tuvalu
U.S. Outlying Islands
U.S. Virgin Islands
Uganda
Ukraine
United Arab Emirates
United Nations
Uruguay
Uzbekistan
Vanuatu
Vatican City
Venezuela
Vietnam
Wallis & Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hPD-1/hPD-L1/hCTLA4 mice
Strain Name C57BL/6-Pdcd1tm1(PDCD1)Cd274tm1(CD274)Ctla4tm1(CTLA4)/Bcgen Common Name  B-hPD-1/hPD-L1/hCTLA4 mice
Background C57BL/6 Catalog number  130571
Related Genes 
PD-1 (Programmed death-1) 

CD274 (CD274 antigen)  

CTLA4 (Cytotoxic T-lymphocyte-associated protein 4,CD152)

NCBI Gene ID
18566,60533,12477

Protein expression analysis

from clipboard


Strain specific PD-1, PD-L1 and CTLA4 expression analysis in homozygous B-hPD-1/hPD-L1/hCTLA4 mice by flow cytometry. 

Splenocytes were collected from WT and homozygous B-hPD-1/hPD-L1/hCTLA4 (H/H) mice stimulated with anti-CD3ε in vivo, and analyzed by flow cytometry with species-specific anti-PD-1, anti-PD-L1 and anti-CTLA4 antibody. Mouse PD-1, PD-L1 and CTLA4 were detectable in WT mice. Human PD-1, PD-L1 and CTLA4 were exclusively detectable in homozygous B-hPD-1/hPD-L1/hCTLA4 but not WT mice.

Analysis of spleen leukocytes cell subpopulations in B-hPD-1/hPD-L1/hCTLA4 mice

from clipboard

from clipboard



Analysis of blood, spleen and lymph node leukocytes cell subpopulations in B-hPD-1/hPD-L1/hCTLA4 mice

from clipboard


Analysis of blood, spleen and lymph node leukocytes cell subpopulations by FACS

Blood, spleen and lymph node leukocytes cell were isolated from female mice in the panel(n=3, 6 week-old). Flow cytometry analysis was performed to assess leukocyte subpopulations. Percent of T, B, NK, Granulocytes, Monocyte, DC and macrophage cells in homozygous B-hPD-1/hPD-L1/hCTLA4 mice were similar to those in the C57BL/6 mice at rest, demonstrating that the humanized mouse does not change the overall development, differentiation or distribution of these cell types in blood, spleen and lymph node.


Analysis of blood, spleen, lymph node T cell subpopulations in B-hPD-1/hPD-L1/hCTLA4 mice

from clipboardfrom clipboard


Analysis of blood, spleen and lymph node T cell subpopulations in B-hPD-1/hPD-L1/hCTLA4 mice

from clipboard


Analysis of blood, spleen and lymph node T cell subpopulations by FACS

Blood, spleen and lymph node leukocytes cell were isolated from female mice in the panel(n=3, 6 week-old). Flow cytometry analysis was performed to assess leukocyte subpopulations. Percent of CD4+T, CD8+T and Tre cells in homozygous B-hPD-1/hPD-L1/hCTLA4 mice were similar to those in the C57BL/6 mice at rest, demonstrating that the humanized mouse does not change the overall development, differentiation or distribution of these cell types in blood, spleen and lymph node.



Blood routine test of B-hPD-1/hPD-L1/hCTLA4 mice

from clipboard


Complete blood count (CBC). Blood from C57BL/6 and B-hPD-1/hPD-L1/hCTLA4 mice (n=5, 6 week-old, female) were collected and analyzed for CBC. Any measurement of B-hPD-1/hPD-L1/hCTLA4 mice in the panel were similar to C57BL/6, and there was no differences between male and female mice, indicating that humanized mouse does not change blood cell composition and morphology. Values are expressed as mean ± SEM.


Blood chemistry of B-hPD-1/hPD-L1/hCTLA4 mice


from clipboard



Blood chemistry tests of B-hPD-1/hPD-L1/hCTLA4 mice. Serum from C57BL/6 and B-hPD-1/hPD-L1/hCTLA4 mice (n=5, 6 week-old, female) were collected and analyzed for levels of ALT, AST and other indicators in the panel. There was no differences on either measurement between C57BL/6 and humanized mouse, indicating that humanized mouse does not change ALT and AST levels or health of liver. Values are expressed as mean ± SEM.


Combination therapy of pembrolizumab, atezolizumab and ipilimumab 


from clipboard


Antitumor activity of pembrolizumab, atezolizumab and ipilimumab in B-hPD-1/hPD-L1/hCTLA4 mice. 

(A) Anti-human PD-1/PD-L1 antibody combined with anti-human CTLA4 antibody inhibited MC38 tumor growth in B-hPD-1/hPD-L1/hCTLA4 mice. Murine colon cancer hPD-L1 MC38 cells were subcutaneously implanted into homozygous B-hPD-1/hPD-L1/hCTLA4 mice (female, 9-10 week-old, n=6). Mice were grouped when tumor volume reached approximately 100 mm3, at which time they were treated with pembrolizumab, atezolizumab and ipilimumab with doses and schedules indicated in panel A. (B) Body weight changes during treatment. As shown in panel A, combination of pembrolizumab/ipilimumab or atezolizumab/ipilimumab shows more inhibitory effects than individual groups, demonstrating that the B-hPD-1/hPD-L1/hCTLA4 mice provide a powerful preclinical model for in vivo evaluating combination therapy efficacy of hPD-1/hPD-L1 antibodies and hCTLA4 antibodies. Values are expressed as mean ± SEM (All antibodies were made in house).